Advertisement
Canada markets close in 5 hours 43 minutes
  • S&P/TSX

    21,713.01
    -160.71 (-0.73%)
     
  • S&P 500

    5,006.00
    -65.63 (-1.29%)
     
  • DOW

    37,809.58
    -651.34 (-1.69%)
     
  • CAD/USD

    0.7296
    -0.0002 (-0.02%)
     
  • CRUDE OIL

    82.42
    -0.39 (-0.47%)
     
  • Bitcoin CAD

    87,329.46
    -3,264.91 (-3.60%)
     
  • CMC Crypto 200

    1,371.45
    -11.12 (-0.80%)
     
  • GOLD FUTURES

    2,330.00
    -8.40 (-0.36%)
     
  • RUSSELL 2000

    1,959.08
    -36.35 (-1.82%)
     
  • 10-Yr Bond

    4.7290
    +0.0770 (+1.65%)
     
  • NASDAQ

    15,468.73
    -244.02 (-1.55%)
     
  • VOLATILITY

    17.52
    +1.55 (+9.71%)
     
  • FTSE

    8,047.10
    +6.72 (+0.08%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6808
    -0.0011 (-0.16%)
     

Analyst Ratings for Nektar Therapeutics and Peers in March 2018

Analyst Ratings for Nektar Therapeutics and Peers in March 2018

Why Are Investors Excited about Nektar Therapeutics in 2018? Nektar Therapeutics (NKTR) is a biopharmaceutical company with investigational drug candidates for the treatment of cancer, autoimmune disease, and chronic pain. Of the nine analysts covering Nektar Therapeutics in March 2018, four of them have given the stock a “strong buy” rating.